A Phase 2 interventional study of THDBH120 injection and Placebo of THDBH120 injection in Overweight or Obese, sponsored by Tonghua Dongbao Pharmaceutical Co.,Ltd. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-06-25.
Sponsored by Tonghua Dongbao Pharmaceutical Co.,Ltd · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 330 studies in Overweight with a site in China — 123 open to participants now, 166 under way, 43 of them phase 3. Overweight · China.
Among the 330 studies in Overweight with a site in China, this one is the 85th largest by planned enrollment of the 296 interventional ones that give a count, is one of 66 that started in 2025, is one of 37 in phase 2, reaches primary completion later than 22 of the 165 other live ones, and was the 172nd registered.
3,613 studies on the registry are indexed under Overweight; 856 are open to participants now.
Browse Overweight studies →123 of the 330 studies in Overweight with a site in China are open now. Recruiting first, the newest first:
Chendu DIAO Pharmaceutical Group CO., LTD. · Sites in China
Ages 18–65
The First Hospital of Jilin University · Sites in China
Ages 18–65
Pfizer · Sites in China
Ages 18+
Eli Lilly and Company · Sites in China, United States, Brazil and 7 more countries
Ages 18+
The United Bio-Technology (Hengqin) Co., Ltd. · Sites in China
Ages 18–55
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 531 Overweight studies recruiting now, 159 (30%) set no upper age limit and 344 (65%) stop at 75 or younger; 63 take children under 18; 205 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
330 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 88 · Phase 2 47 · Phase 3 66 · Phase 4 12
First in 2005; this study’s year is marked. 66 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 276 is above the median of 78 across 3,127 interventional studies indexed under Overweight.
Median enrollment 120 across the 296 interventional studies, 375 across the 34 observational. Of the 145 that completed or were terminated, 9 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
183 of 330 have an industry lead sponsor. The 10 most frequent:
Tonghua Dongbao Pharmaceutical Co.,Ltd is the lead sponsor of 11 studies on the registry; 3 are open to participants now.
Tonghua Dongbao Pharmaceutical Co.,Ltd has 1 study filed under Overweight — fewer than ten, so there is no comparison to draw.
65 of the studies in Overweight with a site in China that are under way reach primary completion within a year, 15 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06884293Phase 3Innovent Biologics (Suzhou) Co. Ltd.A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) | 2026-12-31 |
| NCT06672549Phase 3Eli Lilly and CompanyA Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040) | 2027-02 |
| NCT07481747Phase 3Hudson BiotechEfficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1) | 2027-02-14 |
| NCT07230119Phase 3Beijing QL Biopharmaceutical Co.,LtdA Study of Zovaglutide in Subjects With Overweight or Obesity (HORIZON-1) | 2027-05-29 |
| NCT07274137Phase 3MindRank AI LtdA Phase III Study to Evaluate the Efficacy and Safety of MDR-001 in Adult Participants With Overweight or Obesity (MOBILE) | 2027-06 |
Add all 65 to your calendar (.ics) → With an account.
Among the 330 studies in Overweight with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To assess the efficacy and safety of THDBH120 injection compared with placebo in weight reduction in overweight or obese subjects after 26 weeks of treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: THDBH120 injection
Drug: Placebo of THDBH120 injection
Participants received THDBH120 by subcutaneous injection.
Participants received placebo by subcutaneous injection.
Percentage change in body weight
Time frame: Baseline, Week26
Percentage of Participants Who Achieve ≥5% Body Weight Reduction
Time frame: Baseline, Week26
Percentage of Participants Who Achieve ≥10% Body Weight Reduction
Time frame: Baseline, Week26
Percentage of Participants Who Achieve ≥15% Body Weight Reduction
Time frame: Baseline, Week26
Percentage of Participants Who Achieve ≥20% Body Weight Reduction
Time frame: Baseline, Week26
Change from baseline in waist circumference after the treatment
Time frame: Baseline, Week 26
Change from baseline in BMI after the treatment
Time frame: Baseline, Week 26
Change from baseline in blood pressure after the treatment
Time frame: Baseline, Week 26
Change from baseline in HbA1c after the treatment
Time frame: Baseline, Week 26
Change from baseline in total cholesterol after the treatment
Time frame: Baseline, Week 26
Number of Participants with One or More Adverse Event(s) and Serious Adverse Event(s)
Time frame: Week 30
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2025 (actual). Primary completion is estimated for Feb 2026, 13 months after the start.
Of 102 industry-sponsored phase 2 interventional studies under Overweight, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 16. This study's planned 13 months is close to that.
Counting every sponsor, half of 148 studies reached it within 13 months; a quarter within 8 and three quarters within 21.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: THDBH120
Tonghua Dongbao Pharmaceutical Co.,Ltd